apitegromab tirzepatide Apitegromab, a selective antimyostatin monoclonal antibody targeting muscle preservation, added to reduced muscle loss by ~55% over 24 weeks without affecting overall weight loss in the phase 2 EMBRAZE trial. https://t.co/jDqTipQrZa FDA Grants Tirzepatide a New
Pay in 4 interest-free payments of $5.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6






.png)


.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)



















